How better market research can improve commercial decision-making before launch
Medical device innovation is expensive, complex, and inherently high risk. Significant investment goes into product development, clinical validation, regulatory approval, and commercial launch planning. Yet even highly promising innovations with strong clinical rationale can struggle to achieve expected adoption once they reach the market.
This is where effective market research becomes critical.
Concept testing is one of the most important tools available to med-tech companies during product development. Done well, it helps innovation teams evaluate unmet needs, refine product concepts, strengthen value propositions, and build confidence in strategic decisions before launch. However, concept testing also comes with an important challenge: accurately predicting real-world demand.
Across the med-tech industry, it is common for early-stage concepts to generate highly encouraging feedback. Stakeholders recognise the unmet need, respond positively to the proposed solution, and see clear potential in the value proposition. Internal teams often leave the research feeling confident in the opportunity.
And yet, adoption in-market is often more measured than those early signals suggest.
This does not necessarily mean the innovation lacks value, nor that the research was poorly designed. More often, it reflects the complexity of healthcare decision-making and the difficulty of recreating real-world purchasing behaviour in a research setting.
The core challenge is simple: many concept tests are highly effective at measuring interest, but far less effective at predicting adoption.
That distinction matters more than many teams realise.
Why concept testing often overestimates demand
Traditional concept testing typically places respondents in a simplified decision environment. A concept is introduced, the features and benefits are explained, and stakeholders are asked to evaluate its appeal, perceived value, innovation, or likelihood of use.
This approach generates useful feedback, but it removes much of the complexity that shapes adoption in the real world.
Healthcare purchasing decisions are rarely straightforward. Clinicians operate under time pressure. Procurement teams face increasing cost scrutiny. Hospital administrators are expected to justify investment decisions with clear economic rationale. Existing solutions—however imperfect—are often deeply embedded within clinical workflows and purchasing agreements.
These realities shape decision-making every day.
Yet many concept tests do not fully account for them. Budget pressure may be absent. Switching costs may be overlooked. Operational disruption may be underestimated. Procurement barriers may not be fully considered.
Under these conditions, it is relatively easy to generate strong theoretical interest.
The problem is that theoretical interest and real-world adoption are not the same thing. A concept can perform extremely well in research while still facing significant barriers once introduced into clinical practice.
This is where demand can be unintentionally overestimated.
In med-tech, clinical value alone is rarely enough
One of the defining characteristics of med-tech is that adoption decisions are rarely driven by product performance alone.
Clinical value matters enormously, but it is typically only one part of a much broader commercial equation.
We frequently see innovations with compelling clinical benefits and strong user feedback face slower adoption than expected because other barriers remain unresolved. A product may improve outcomes, reduce complications, or deliver a better user experience, yet still struggle if it creates workflow disruption, lacks economic justification, or fails to align with the priorities of key stakeholders.
This is especially true for premium innovations, capital equipment, digital health solutions, and technologies that require meaningful behavioural change.
A surgeon may need to alter established procedural habits. A nurse may need to adopt a new workflow. Procurement may require stronger evidence of value. Hospital leadership may need confidence that higher upfront costs will translate into measurable downstream savings.
Each of these factors introduces friction into the adoption process.
In our experience, this friction often tells you far more about likely adoption than early enthusiasm alone.
This is also why stakeholder complexity matters so much in healthcare. The end user is often not the buyer, and the buyer is often not the sole decision-maker. A concept may resonate strongly with clinicians while facing meaningful resistance from procurement, finance, or senior leadership.
Without understanding the full decision ecosystem, it becomes very difficult to accurately assess market potential.
The best concept tests focus on resistance, not just interest
At IDR, one principle consistently shapes how we approach concept testing: measuring interest alone is rarely enough.
The strongest programmes are designed to understand resistance as well as excitement.
Rather than focusing purely on whether stakeholders like a concept, the objective becomes understanding what could slow or prevent adoption. Where does hesitation emerge? What concerns remain unresolved? What evidence is missing? What would need to change to strengthen adoption potential?
These questions often produce the most commercially valuable insights.
In many cases, the greatest opportunities do not come from understanding why customers are excited. They come from understanding why they hesitate.
Resistance often reveals the barriers that matter most—whether that is pricing, workflow disruption, insufficient differentiation, weak economic evidence, or poor stakeholder alignment.
The most valuable concept testing does not simply measure appeal.
It pressure-tests commercial viability.
Choosing methodologies that better predict adoption
Better concept testing does not require abandoning traditional research methodologies. Qualitative and quantitative research remain essential. The difference lies in how these approaches are designed and combined.
Qualitative research remains particularly valuable in early-stage development because it helps uncover unmet needs, behavioural barriers, workflow challenges, and hidden objections. It provides the depth needed to understand why stakeholders react the way they do and where hesitation begins.
Quantitative research becomes especially powerful when used to validate opportunity at scale. However, studies focused purely on concept appeal or purchase intent often provide an incomplete picture. The strongest quantitative programmes explore switching behaviour, barriers to adoption, and the triggers required to drive uptake.
More advanced methodologies can provide even stronger predictive value. Approaches such as MaxDiff and Conjoint are particularly effective because they force stakeholders to make trade-offs. Rather than evaluating a concept in isolation, respondents must prioritise competing attributes and make decisions under realistic constraints.
Pricing research also plays a critical role and is often introduced too late. A concept may perform strongly on perceived value and clinical relevance, only for willingness to pay to emerge as the primary barrier to adoption.
The strongest research programmes combine multiple methodologies to build a realistic and nuanced view of market potential.
Good research improves commercial decision-making
Ultimately, the purpose of concept testing is not to generate reassuring feedback or validate internal assumptions.
Its purpose is to improve decision-making.
The strongest research programmes help teams identify adoption barriers early, evaluate market potential more accurately, and make smarter strategic decisions before major commercial commitments are made.
At IDR, we help med-tech companies design research programmes that go beyond measuring concept appeal. Our focus is on understanding what will drive adoption, what may limit it, and what needs to be addressed to maximise commercial success.
Good concept testing does not simply validate ideas.
It challenges them.
And the best concept testing programmes do not stop at asking whether a concept sounds appealing.
They answer the far more important question:
Will this succeed in the real world?
Speak to IDR Medical
At IDR Medical, we specialise in medical device market research, supporting med-tech companies with concept testing, unmet needs research, pricing strategy, value proposition development, and commercial strategy.
Our team helps clients generate the evidence and insights needed to make better product, pricing, and go-to-market decisions with confidence.
If you are developing a new medical device, digital health solution, or healthcare service and want to better understand market demand, adoption barriers, or commercial opportunity, we would be happy to discuss how we can help.
Contact IDR Medical to learn more.